Currently, nivolumab, an immune checkpoint inhibitor, in combination with oxaliplatin and fluoropyrimidines is a standard therapy for HER2-negative unresectable advanced or recurrent gastric cancer on the basis of recent phase III studies [24,25], raising the issue of whether SOX or CapeOX should be used as backbone chemotherapy. The gene discussed is ERBB2; the disease is gastric cancer.